BNFC August 2024 Update

This update contains 4 significant changes, 1 dose change, and 3 new monographs.

Significant Changes:
•Immunisation schedule: updated guidance for immunisation against influenza.
•Influenza vaccine: updated guidance for immunisation.
•Medical emergencies in the community: updated guidance on the use of salbutamol in the management of acute asthma.
•Topical corticosteroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions [MHRA/CHM advice] (advice in relevant monographs; see example in betamethasone).

Dose Changes:
•Salbutamol [update to dosing for asthma; prophylaxis of allergen-or-exercise-induced bronchospasm; and exacerbation of reversible airways obstruction].

New Monographs:
•Biktarvy® [bictegravir with emtricitabine and tenofovir alafenamide].
•Finlee® [dabrafenib].
•Spexotras® [trametinib].